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Abstract 
Background: Onchocerciasis is a priority neglected tropical disease targeted for elimination by 2025. The standard 
strategy to combat onchocerciasis is annual Community‑Directed Treatment with ivermectin (CDTi). Yet, high preva‑
lence rates and transmission persist following > 12 rounds in South‑West Cameroon. Challenges include programme 
coverage, adherence to, and acceptability of ivermectin in an area of Loa loa co‑endemicity. Loiasis patients harbour‑
ing heavy infections are at risk of potentially fatal serious adverse events following CDTi. Alternative strategies are 
therefore needed to achieve onchocerciasis elimination where CDTi effectiveness is suboptimal.
Methods/design: We designed an implementation study to evaluate integrating World Health Organisation‑
endorsed alternative strategies for the elimination of onchocerciasis, namely test‑and‑treat with the macrofilaricide, 
doxycycline (TTd), and ground larviciding for suppression of blackfly vectors with the organophosphate temephos. 
A community‑based controlled before‑after intervention study will be conducted among > 2000 participants in 20 
intervention (Meme River Basin) and 10 control (Indian River Basin) communities. The primary outcome measure 
is O. volvulus prevalence at follow‑up 18‑months post‑treatment. The study involves four inter‑disciplinary compo‑
nents: parasitology, entomology, applied social sciences and health economics. Onchocerciasis skin infection will 
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Background
Onchocerciasis (river blindness) is a vector-borne, 
neglected tropical disease (NTD), caused by the filarial 
parasite Onchocerca volvulus. Physical manifestations 
include troublesome itching, skin rash, visual impair-
ment and irreversible blindness [1–3]. Currently, the 
World Health Organization (WHO) through the African 
Programme for Onchocerciasis Control (APOC) and, lat-
terly, The Extended Special Programme for the Elimina-
tion of NTDs (ESPEN), is using mass drug administration 
(MDA) with ivermectin (IVM) to move towards disease 
elimination. Ivermectin is a microfilaricidal drug that 
kills the immature larval form of the parasite, microfilar-
iae (mf) found in the skin, to prevent disease and trans-
mission to the blackfly vector [4, 5]. Based on predictive 
model simulations, the WHO recommends that annual 
MDA for at least 15–17 years with high population cov-
erage (80%) may impact on transmission and thus abate 
incidence of skin infection in younger individuals [1, 6]. 
MDA has been conducted in the South-West region of 
Cameroon for more than 12 years in a strategy known as 
Community-Directed Treatment with IVM (CDTi), yet 
higher than expected prevalence and intensity of oncho-
cerciasis persists including in children born in the CDTi 
period [7–9].
The persistence of onchocerciasis in South-West 
Cameroon highlights that a transition from control 
to elimination of this disease using CDTi is likely to 
be complicated by multiple factors. Of major concern 
is the geographical overlap with the related filarial, 
Loa loa, which is a risk factor for incidence of severe 
(neurological) adverse events (SAE), as well as more 
frequent non-neurological adverse events (AE), post-
CDTi [10, 11]. The perception of IVM-related SAE 
may impinge on adherence to CDTi even in areas free 
from L. loa [9]. Therefore, an urgent need exists to vali-
date and implement alternative strategies to accelerate 
elimination of onchocerciasis, as well as to more fully 
understand structural and health system factors and 
social and contextual reasons for sub-optimal success 
of the CDTi strategy so that these may be avoided in 
the future, especially in areas of L. loa co-endemicity.
The objective of this research study is to assess the 
effectiveness, acceptability and feasibility of a test-and-
treat strategy for onchocerciasis control using the WHO 
endorsed macrofilaricidal treatment, doxycycline (Test 
& Treat with doxycycline; TTd), a potential alternative 
for IVM. Doxycycline (DOX) differs from IVM as it tar-
gets the filarial symbiont, Wolbachia, which sterilises 
adult worms residing in human tissues, preventing the 
production of mf seeding the skin and also significantly 
reduces adult lifespan to mediate macrofilaricidal activity 
within two years post-treatment [12, 13]. Further benefit 
of depleting Wolbachia in existing skin mf is the inhibi-
tion of development to infectious stage larvae within 
the blackfly vector, thus more immediately impacting 
on transmission [14]. Doxycycline does not cause rapid 
microfilaricidal activity, and its target, Wolbachia, is not 
present in L. loa [15–17]. Therefore, DOX does not trig-
ger IVM-like inflammatory AE and is completely safe in 
the treatment of onchocerciasis/loiasis co-infection. Our 
hypothesis is that by offering an alternative treatment to 
IVM, community members who are reluctant to engage 
with the CDTi approach due to factors listed above will 
be able to access treatment for onchocerciasis. In addi-
tion, the recent success of ground larviciding to reduce 
biting incidence of the O. volvulus vector, Simulium 
(blackfly), will be implemented in addition to TTd to 
evaluate if there is added benefit in combining alternative 
strategies [18–20].
be diagnosed by skin biopsy and Loa loa infection will be diagnosed by parasitological examination of finger‑prick 
blood samples. A simultaneous clinical skin disease assessment will be made. Eligible skin‑snip‑positive individuals 
will be offered directly‑observed treatment for 5 weeks with 100 mg/day doxycycline. Transmission assessments of 
onchocerciasis in the communities will be collected post‑human landing catch of the local biting blackfly vector 
prior to ground larviciding with temephos every week (0.3 l/m3) until biting rate falls below 5/person/day. Qualitative 
research, including in‑depth interviews and focus‑group discussions will be used to assess acceptability and feasibility 
of the implemented alternative strategies among intervention recipients and providers. Health economics will assess 
the cost‑effectiveness of the implemented interventions.
Conclusions: Using a multidisciplinary approach, we aim to assess the effectiveness of TTd, alone or in combination 
with ground larviciding, following a single intervention round and scrutinise the acceptability and feasibility of imple‑
menting at scale in similar hotspots of onchocerciasis infection, to accelerate onchocerciasis elimination.
Keywords: Onchocerciasis, Onchodermatitis, Wolbachia, Doxycycline, Cameroon, Vector Control, Temephos, Abate, 
NTD Elimination, Multi‑disciplinary
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Methods/design
Study design and objectives
The implemented study is a community-based con-
trolled longitudinal intervention study which con-
sists of a baseline survey and a follow-up survey 18 
months after the commencement of the interventions. 
The interventions consist of three study arms: CDTi 
approach as normal (Study Arm 1); testing and treat-
ing community members with DOX alone (Study Arm 
2); or in combination with temephos (abate) ground 
larviciding (Study Arm 3). Additionally, all study par-
ticipants will be advised to adhere to CDTi unless their 
diagnosis results for L. loa indicate a risk of loiasis 
SAE. Control community clusters (Study Arm 1) will 
continue the standard control strategy only (CDTi). 
A quantitative approach will be used to assess the 
effectiveness of the implemented interventions and 
qualitative research methods including interviews, 
focus-group discussions, observations of the test-and-
treat process and implementer field diaries reflecting on 
the research will be used to assess the perceptions and 
attitudes towards CDTi, as well as the acceptability and 
feasibility of the implemented interventions amongst 
community drug distributors (CDDs) and study partici-
pants of TTd and ground larviciding communities.
The objectives of this study are to:
 (i) Determine the major community participant and 
community drug distributor attitudes associated 
with sub-optimal effectiveness of the current CDTi 
strategy;
 (ii) Assess the acceptability and feasibility of imple-
menting alternative strategies for onchocerciasis 
elimination (namely TTd and ground larviciding);
 (iii) Determine the effectiveness of implementing TTd 
and ground larviciding in accelerating focal elimi-
nation of onchocerciasis.
Study area and site selection
The study is conducted in the Rumpi Hills region, South-
West Cameroon. The area is characterized by a volcanic 
ridge culminating at 1764 m from which the Meme, 
Mungo, Manyu, and Ndian rivers take their waters. 
These fast-flowing rivers provide perennial breeding 
sites for the major O. volvulus blackfly vector, Simulium 
damnosum (s. l.), leading to continuous onchocerciasis 
transmission.
The climate is characterized by high temperatures 
(25–32  °C), heavy rainfall (2500–4000 mm) for seven 
months of the year (April-November) and a short dry 
season from December to March. An evergreen and 
humid forest is the main feature of this zone although it 
is gradually being replaced by plantations (rubber, palm 
oil, cocoa, coffee, food crops) [21].
Onchocerciasis prevalence data collected in 2012 
indicated ongoing transmission in the Meme, Mungo 
and Manyu river basins [7]. The Meme basin exhib-
ited the highest mean skin mf prevalence (52.7%) with 
prevalence rates above 40% in 13/16 communities 
examined, as well as the highest intensity of infection 
and prevalence of nodules [7]. This area was selected 
so implementing alternative strategies could have most 
impact.
Each study intervention arm (Arm 2: DOX only and 
Arm 3: DOX+VC) will include 10 communities located 
in the Meme River Basin. The 10 communities of the con-
trol arm (Arm 1) will be selected from the nearby Ndian 
River Basin. Study sites are displayed in Fig. 1. Commu-
nity selection was based on hydrological mapping, to 
achieve maximum spatial segregation between vector 
control and non-vector control study sites.
Pre‑study processes
Advocacy and stakeholder engagement
Advocacy and stakeholder engagement meetings will be 
organised and held at different levels of the health sys-
tem from the national to the community level. They will 
involve key health system stakeholders and community 
leaders who will communicate the information to their 
respective areas of influence and communities. A key 
issue will be to collect baseline parasitological data before 
CDTi takes place in the study communities.
Community entry and sensitisation
As a first entry point to the communities, community 
leaders will be invited to all stakeholder and advocacy 
meetings. Following this, community leaders and health 
systems stakeholders will be engaged in sensitising other 
community members in all 20 intervention communities.
Training of health workers and CDDs
The district and health area staff will be trained by the 
research team, and the Chiefs of Health Centres will cas-
cade the training to CDDs, community leaders, religious 
leaders, and Community Based Organisations. Training 
activities will be supervised and monitored by the health 
district staff and the research team. CDDs will receive 
TTd specific training, which will include drug packaging, 
directly observing treatment with DOX, filling of regis-
ters, following up of participants, monitoring side effects, 
managing minor side effects and evaluating the entire 
process.
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Study participants
Population census
A community census will be carried out in all 30 study 
communities to evaluate the population eligible for 
screening. All individuals aged 5 years and above and 
who will have lived in the community for five years or 
more at the time of the census will be eligible for the par-
asitological screening.
Enrolment in the intervention study and eligibility criteria
All censused individuals will be explained the objectives 
and procedures of the intervention study and informed 
assent/consent will be obtained before enrolment. For 
children and adolescents, assent will be obtained using 
information sheets specifically designed for children (age 
below 15 years) and adolescents (age 15–18 years) and 
consent will be obtained from a parent or legal guardian.
Participants enrolled in all study arms will be tested 
for O. volvulus and L. loa infection. Only microfilari-
dermic (individuals diagnosed with O. volvulus infec-
tion), who consent to participate and meet the eligibility 
criteria to take DOX will be enrolled in the intervention 
study. Children below 9 years-old, pregnant and breast-
feeding women, individuals suffering from any chronic 
disease (hypertension, diabetes, tuberculosis, HIV/AIDS) 
and those on other daily medications will be excluded 
from DOX treatment due to potential adverse reactions. 
All microfilaridermic women of childbearing age (15–
49  years) will be tested for pregnancy, with their con-
sent, using hCG Urine Pregnancy Test Strip (LabACON, 
Lancing, UK). Women with a negative test will be advised 
to avoid any occurrence of pregnancy during treatment 
(abstinence or contraceptive use). Results of pregnancy 
testing will be communicated verbally to female patients 
in private.
Participants in the qualitative assessments
Community members, health system implementers 
of TTd and ground larviciding implementers will be 
recruited for semi-structured interviews and focus-group 
discussions. Table 1 summarises the planned number of 
qualitative interviews.
Interviews will take place to assess the perception and 
acceptability of the CDTI strategy and the new TTd 
strategy. Interview participants will be representative of 
community members participating in the census who 
refused to be screened (skin-snipped), O. volvulus-neg-
ative participants who refuse CDTi, O. volvulus-positive 
Fig. 1 Map of the study area indicating spatial segregations of intervention community clusters
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participants who either refused or accepted DOX, as well 
as influential community members (key informants). 
CDDs and Chiefs of Health Centres will be interviewed 
to investigate perceptions of the TTd strategy from a 
health system implementers perspective.
Participants in the health economic analysis
A purposive sampling technique will be used to enrol 
households eligible for outcome assessments. A sampling 
frame of all eligible participants will be obtained from 
CDD and community health workers.
Treatment procedure
All enrolled participants will be treated with 100 mg 
DOX daily for five weeks. DOX capsules will be pro-
cured from a UK wholesale pharmaceutical supplier and 
shipped from UK at ambient temperature, to be used 
within 6 months.
The treatment will be delivered using an enhanced 
CDTi approach under direct supervision [22]. A maxi-
mum of 10 patients will be allocated to each CDD for 
daily administration. CDDs will be compensated for 
earnings missed during the treatment delivery period by 
payment of 1000 CFA per day. Treatment will be taken 
with a food provided by the research team, to avoid 
potential gastric side effects to DOX. Participants shall 
swallow the DOX capsule in the presence of the CDD 
(directly observed treatment) and treatment uptake will 
be recorded in registers. If enrolled individuals are absent 
due to work or other commitments, capsules will be sup-
plied to them, and empty blister packs returned to the 
community health implementer for monitoring of adher-
ence. A member of the research team will be assigned to 
each community to supervise treatment activities of the 
CDDs.
All diagnosed onchocerciasis patients and/or loiasis 
patients will be verbally informed of their infection sta-
tus. Irrespective of eligibility to DOX treatment, patients 
will be advised to adhere to CDTi unless they are diag-
nosed with L. loa microfilaremia > 8000 mf/ml. Any such 
patient will be offered a 400 mg albendazole treatment. 
The flow chart (decision tree) of the test-and-treat with 
DOX is as shown in Fig. 2.
Assessment of doxycycline‑related adverse events
Clinical monitoring of adverse reactions (AEs) will be 
undertaken by community health workers throughout 
the 5-week period of DOX treatment under the supervi-
sion of the research monitors and the chief of the local 
health centres. Patients will be asked by questionnaire for 
any side effects of the drugs as per protocol. AEs will be 
graded as absent, mild, moderate or severe. Individuals 
will be asked to report any signs and symptoms that were 
not experienced prior to drug administration. All symp-
toms will be documented in patients’ treatment cards 
and medication or hospitalisation will be provided where 
necessary.
Quantitative assessments
Demographic and treatment intake history assessments
All censused participants will be asked to answer a struc-
tured questionnaire to collect data on socio-demograph-
ics, self-reported adherence to CDTi and albendazole 
intake history.
For the control communities, a minimum census sur-
vey recording age and gender will be conducted to keep 
interactions with, and interference by the study at a 
minimum.
Table 1 Summary of qualitative interviews
Abbreviations: CDD, community drug distributor; na, not applicable
Group interviewed Study Arm 2 Study Arm 3 Total
Men Women Men Women
Refusers at screening phase 2–4 2–4 2–4 2–4 8–16
Onchocerciasis negative and refuse ivermectin 2–4 2–4 2–4 2–4 8–16
Refusers of doxycycline 2–4 2–4 2–4 2–4 8–16
Acceptors of doxycycline 6–12 6–12 6–12 6–12 24–48
Post‑training interviews with CDDs 2–4 2–4 2–4 2–4 8–16
Post‑intervention interviews with CDDs 2–4 2–4 2–4 2–4 8–16
Post‑training interviews with chief of centre 2–3 2–3 4–6
Post‑intervention interviews with chief of centre 2–3 2–3 4–6
Key Informant interviews with influential community 
members
4–8 4–8 8–16
Ground larviciding implementers na 4–8 4–8
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Parasitological assessments
• Onchocerciasis testing. Onchocerciasis diagnosis 
will be offered via the gold-standard method of skin 
biopsy (skin snipping). Two bloodless skin biopsies 
will be taken from the left and right iliac crest of 
each participant using a sterile 2 mm corneo-scleral 
punch (CT 016 Everhards 2218-15 C, Meckenheim, 
Germany). Each participant skin sample will be 
incubated in 2 separate wells of a sealed microtiter 
plate containing 2 drops of normal saline for 24  h. 
The medium will be examined under a light micro-
scope. Emerged mf will be counted and expressed per 
biopsy (which corresponds approximately to 1 mg of 
Fig. 2 Doxycycline treatment decision tree with inclusion and exclusion criteria. Abbreviations: ABZ, albendazole; CDTi, community directed 
treatment with ivermectin; DOX, doxycycline; mf, microfilariae; ml, millilitre
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skin; mf/mg) [7, 23]. The skin biopsies and any emer-
gent mf will be placed into 1.5  ml Eppendorf tubes 
and 80% ethanol added and stored at −80 °C for sub-
sequent use (DNA extraction).
• Loiasis and other blood-borne filariae testing. Study 
participants will undergo a finger prick blood test 
for L. loa, to quantify the potential for loiasis adverse 
reactions to the standard CDTi treatment only, as 
L. loa is not impacted by DOX [13]. A 50 µl blood 
smear will be prepared, dehaemoglobinised for 
5–15  min, and fixed with methanol. Smears will be 
stained in 10% Giemsa for 45 min and allowed to air-
dry [24]. Microfilariae of L. loa and/or M. perstans 
will be identified using microfilarial identification 
keys [25]. Slides will be read by trained technicians 
and counts will be expressed as the number of micro-
filariae per millilitre (mf/ml) of blood.
Onchodermatitis clinical assessments
Enrolled participants will undergo a clinical skin assess-
ment conducted by nursing staff from local district hos-
pitals, using a standardised clinical classification and 
grading system for onchodermatitis [26]. The nurses 
will be specifically trained by an expert dermatologist in 
onchocercal skin disease assessment and coding. Each 
assessor will be evaluated by inter-observer variation 
kappa analysis after conducting examinations on a cohort 
of 20 individuals with known onchodermatitis manifes-
tations. Assessors with  moderate  or higher  agreement 
with the trainer  (kappa 0.41–0.6 and above)  in diagnos-
ing skin disease type  will be utilised in enrolment sur-
veys. Clinical assessments will be conducted in a private 
room within the community, for example within health 
centres or schools. The aim of skin assessments is to eval-
uate burden of onchodermatitis in the communities and 
evaluate effectiveness of CDTi in prevention of oncho-
dermatitis in younger age-groups, related to adherence/
participation in CDTi administrations.
Monitoring of doxycycline treatment efficacy
As an early surrogate biomarker of long-term treat-
ment efficacy, a sub-set of 50 individuals who have ≥ 10 
mf/mg skin pre-treatment and have adhered to 5-week 
treatment with DOX will be selected. Four months post-
commencement of treatment, individuals will be sampled 
for mf by skin biopsy. Numbers of mf and the number of 
Wolbachia per mf will be determined by quantitative pol-
ymerase chain reaction (PCR) [27].
Sample size determination
The planned sample size is 800 participants per study 
arm and 10 community clusters per arm. The sample 
size was estimated using a cluster sampling approach 
assuming a baseline mf prevalence of 52.7% based on 
a survey conducted in the Meme River Basin in 2012, 
a power of 80%, a precision of 5% and a minimum post 
treatment reduction in community prevalence of skin 
microfilaria of 37% [7, 27].
Assuming a population of 2000 individuals and an 
average of about 65 participants per community, it 
was estimated that 685 individuals would be assessed 
against inclusion and exclusion criteria for enrolment 
into the intervention arms. This number was rounded 
up to 800, given that 65 is only the average number 
of people per cluster and that the population size has 
likely increased between 2012 and 2016. The number of 
clusters was estimated using the Hayes & Bennet for-
mula assuming 65 individuals per cluster, a power of 
80%, a precision of 5% and a between-cluster coefficient 
estimated to be 0.27, and was further inflated by 20% 
to allow for loss to follow up and adjustment for poten-
tial confounders at baseline, resulting in a number of 10 
clusters per arm.
Quantitative data management
Data on population census of study communities will 
be collected using the ODK (Open Data Kit, July 2010, 
http://opend ataki t.org) android application pre-installed 
in Samsung Galaxy Tablets. A data collection template 
will be designed in ODK to collect demographic infor-
mation of community members. After house to house 
registration of all members within different households 
(permanent residents), information will be uploaded to a 
cloud server daily for backup and later export to Micro-
soft Excel (2013).
During the parasitological/clinical screening phase, 
eligible study participants will be registered using either 
a template (for parasitology) designed in the Epi info 
version 3.5.2 (EpiData Association, Odense, Denmark) 
android application pre-installed in Samsung Galaxy 
Tablets or paper record forms (clinical examinations). 
Baseline parasitology data will be exported to Microsoft 
Excel (2013). Census and parasitology databases will be 
combined before exportation to a statistical software.
Participant paper clinical records will be stored in 
locked cabinets with restricted access at the University 
of Buea, Cameroon. Electronic participant records will 
be saved at University of Buea on password-protected 
laptop PC and backed up daily onto password-protected 
external hard disk drive which will be stored in a locked 
cabinet with restricted access and will be encrypted and 
stored on a highly-secured password protected server at 
the LSTM. Data will be stored for 10 years after the end 
of the study.
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Quantitative data analysis
The primary outcome is the change in O. volvulus prev-
alence (assessed by the presence of skin mf ) 18 months 
after the start of the treatment. Prevalence rates will 
be reported for each study arm, i.e. TTd only (n = 10 
communities), TTd + VC (n = 10 communities) and the 
standard care group (n = 10 communities), as well as 
for each study community. The impact of each interven-
tion (TTd only and TTd + VC) on O. volvulus infection 
status at follow-up will be assessed using a multivari-
ate mixed effects logistic regression model with inter-
vention as a fixed effect and community as a random 
effect. The model will adjust for potential imbalanced 
participants characteristics between the study arms and 
potential individual-level or village-level confounders 
such as age, gender, occupation, or proximity to fast-
flowing water sources.
The secondary outcome is intensity of O. volvu-
lus infection, defined as skin microfilaridermia, and 
will be recorded as the number of mf per skin snip at 
baseline and at two-year follow-up. As microfilarider-
mia typically follows a negative binomial distribution 
in an endemic cohort, the impact of treatment on the 
intensity of skin mf infection will be analysed similarly 
to infection status but using multivariate mixed effect 
model accounting for overdispersion such as the Nega-
tive Binomial regression.
All statistical analysis will be conducted with input and 
guidance from members of the LSTM clinical tropical 
trials unit.
Entomological assessments
Site survey: identification of S. damnosum breeding sites 
and determination of treatment points
The Meme River and its tributaries (Meme River Basin) 
will be surveyed to identify breeding sites harbouring S. 
damnosum larvae and to collect adult flies to determine 
biting rates. Any mature larvae (6 and 7 stages) found 
will be preserved in Carnoy solution for cytotaxonomic 
studies. All identified breeding sites will be georeferenced 
using a global positioning system (GPS). The coordi-
nates will be used to generate a topographical map of the 
breeding sites.
Larval susceptibility testing
The larvicide temephos (Abate® 500 EC-BASF, Douala, 
Cameroon), will be diluted to give a series of concen-
trations ranging between 0.5–0.0005  mg/l. Larvae of S. 
damnosum will be collected from several representative 
breeding sites in the Meme River Basin. The larvae will 
be exposed to the different concentrations of temephos 
for a period of 3  h after which mortality will be deter-
mined using the WHO criteria [28–30].
Blackfly collection
Human landing catches, the current gold standard, will 
be used to collect blackflies for morphological identifica-
tion, dissection and calculation of entomological indices 
(biting, parous, infection and infective rates including 
transmission potentials) [31]. Collectors will be informed 
of the risk of exposure to onchocerciasis and will receive 
prophylactic treatment with doxycycline (100  mg/day) 
during the collection period and for two weeks follow-
ing collection (up to a total period of 6 weeks). Collec-
tions will be conducted daily for up to five days at two 
geographically separate collection sites within the TTd or 
CDTi community areas [32]. Teams comprising two col-
lectors will work at each site for a 5- and 6-hour period, 
with one collector working from 7:00  h to 12:00  h and 
the second collector working from 12:00  h to 18:00  h. 
The location and time will be rotated among collectors to 
reduce any bias in exposure risk [33].
Ground larviciding
The Onchocerciasis Control Programme (OCP) standard 
larviciding concentration of 0.3 l of Abate/m3 of flow rate 
will be used. Initial assessments of the “larvicide carry”, 
i.e. the distance downstream where the larvicide remains 
effective, will determine the number of river/tributary 
treatment points. It is envisaged that the larviciding will 
proceed for ≥ 4 weeks depending on impact on Simu-
lium larvae but will not exceed 10 weeks. Ground larvi-
ciding will be stopped when the biting rate goes below 5 
bites/person/day.
Monitoring impact on adult and larval blackfly population
Weekly adult blackfly catches will be done using human 
landing catches as described above. Collections shall 
begin two weeks before the start of larviciding and con-
tinue weekly at the same catching points until the com-
pletion of larviciding. Twenty-four hours after each 
larviciding exercise, all known breeding sites will be 
checked for the presence or absence of larvae to ascertain 
the efficacy of the larvicide.
Monitoring impact on non‑target fauna
There will be both short and long-term monitoring of 
effect of temephos implementation over 4–10  weeks 
on the non-target fauna including invertebrates (drift-
ing, benthic) such as shrimps and crabs, and verte-
brates including, tadpoles and fish, commonly Barbus 
and Clarias. Before larviciding, fishermen/women will 
be contacted to find out the composition of their regu-
lar catches (fish, tadpoles, shrimps, crabs) and these will 
Page 9 of 13Wanji et al. Parasites Vectors          (2019) 12:574 
constitute the reference non-target fauna. This protocol 
will keep to WHO/OCP standards by selecting 3 dosing 
points for monitoring at each treatment site. The first 
point (non-treated zone) will be 500 m upstream from 
the treatment point, the second and third will be 100 m 
and 500 m downstream, respectively. Monitoring will be 
done one-week before larviciding and at 5- and 9-weeks 
post-larviciding. Two further monitoring rounds will be 
carried out at 6- and 12-months post-larviciding.
Entomological data management
Flies collected at different hours of the day will be 
recorded singly on designed data collection sheets. Each 
fly will be dissected, and its physiological age and infec-
tion status recorded. Each fly information will be keyed 
in a template designed in EPI info version 3.5.2 (EpiData 
Association, Odense, Denmark) and exported to Micro-
soft Excel (2013) for cleaning and subsequent exportation 
for analysis with a statistical software.
Entomological indices will be calculated as follows:
• Monthly biting rate: (No. of flies × No. of days in 
month)/No. of fly collection days
• Monthly transmission potential: (No. of days in 
month × No. of infectious larvae)/No. of fly collec-
tion days × (No. of flies collected /No. of flies dis-
sected)
Monthly biting rate and monthly transmission poten-
tial will be compared longitudinally (baseline vs 2-year 
follow-up) using paired t-tests. Further modelling 
approaches will be developed in consultation with lead-
ing experts on blackfly control. Both internal and exter-
nal vector control specialists have been invited to advise 
on logistical aspects and data analysis of this part of the 
study.
All statistical analyses will be conducted with input and 
guidance from members of the LSTM Clinical Tropical 
Trials Unit.
Qualitative assessments
An overview of the qualitative study phases is presented 
in Fig. 3.
Observation of implementation of the test‑and‑treat process
Using observation guides, members of the research team 
will observe and document the activities at the differ-
ent workstations, capturing information pertaining to 
the behavioural patterns of the participants and other 
aspects of the research implementation.
Fig. 3 Overview of the qualitative study. Arm 1: control/enhanced monitoring/health systems as usual; Arm 2: test‑and‑treat with doxycycline; Arm 
3: test‑and‑treat with doxycycline and vector control with ground larviciding. Abbreviations: DOX, doxycycline; IVM, ivermectin
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Field diaries of community screeners
Community screeners (those who are involved in skin 
assessment, nodule palpation, skin snip or finger prick 
blood tests), will be asked to keep a field diary of their 
experience and observations when completing the com-
munity screening process, including details on challenges 
experienced, screening refusal, or support by community 
members. Four members of each community screening 
team (one per screening activity: skin assessment, nod-
ule palpation, skin snip and finger prick blood test) will 
be asked to keep a field diary in the intervention study 
arms (Arms 2 and 3). Across all interview sub-categories, 
maximum variation in age and gender of respondent was 
aimed for from the total sample frame. At the end of the 
community screening phase, participants will be asked to 
talk through key elements of their observations.
Semi‑structured interviews
Between 8 and 16 interviews will be conducted with 
those who refuse at the community screening phase to 
understand current health related complaints that could 
be linked to onchocerciasis, experience of the CDTi pro-
gramme, and reasons why they have refused to be part 
of the community screening for the alternative control 
strategy.
Between 8 and 16 interviews with people who are 
onchocerciasis-negative and refused CDTi will be con-
ducted to explore reasons why people do or do not take 
IVM as well as their reaction to receiving a negative diag-
nosis for onchocerciasis.
Between 8 and 16 interviews with those who are 
onchocerciasis-positive but refuse DOX will be con-
ducted to explore reasons why people refuse DOX.
Between 24 and 48 interviews with participants who 
accepted the DOX treatment will be conducted with 
those who agreed to take DOX to explore their experi-
ence of the DOX treatment and its impact on any pre-
existing skin complaints as perceived by the participants.
Between 8 and 16 Key Informant interviews with influ-
ential community members will be completed to explore 
community perceptions of the intervention.
Between 8 and 16 semi-structured interviews will be 
conducted with CDDs and between 4 and 6 with Chief 
of Centres who were trained as part of the TTd control 
strategy to understand current community contexts in 
relation to onchocerciasis and CDTi, and to allow for the 
evaluation and strengthening of the training process.
Interviews with health systems implementers of the 
alternative control strategy will be conducted with CDDs 
(8–16 interviews) and Chief of Centres (4–6 interviews) 
following completion of the alternative control strategy 
to explore perceptions of the entire strategy from a health 
system implementers perspective.
Following completion of ground larviciding activi-
ties, between 4 and 8 interviews will be completed with 
individuals applying the treatment to the river. These 
interviews will explore how individuals were recruited, 
trained and what were their experiences during the inter-
vention period.
Focus group discussions with community members 
about ground larviciding
Following completion of ground larviciding activities, 
focus group discussions will be completed with commu-
nity members to understand perceptions of ground lar-
viciding and the perception of insects and disease in the 
community. Groups will be conducted with men, women 
and youths.
Qualitative data analysis
Interviews and focus group discussions will be recorded 
and transcribed verbatim. The transcripts and field notes 
will be managed using AtlasTi (www.atlas ti.com) or 
NVIVO 10 (QRS Software, Melbourne). A framework 
approach will be used to analyse the data which includes: 
(i) Familiarisation with the data during which time the 
team will read and re-read the data to identify common 
or recurring themes; (ii) Developing a thematic/coding 
framework-based on research aims and objectives and 
any inductive themes identified during the familiarisation 
process; and (iii) Indexing/coding data: the thematic/
coding framework will be applied to all the data by the 
research team. This will then be followed by an explora-
tive phase of charting the data [34]. The final stage will 
be mapping, which is a process to interpret and map the 
range of polarities and similarities within the data. All 
qualitative analyses will be completed by core members 
of the social science team, and analysis and findings dis-
cussed with a wider audience at key points within the 
study. This process will support in enhancing the trust-
worthiness of the research findings [34].
Health economics specific methodology
Economic analyses of the proposed intervention will 
apply cost-effectiveness and cost-benefit analyses. The 
cost-effectiveness analysis will compare the intervention 
alternatives (TTd and TTd+VC) in their costs and effec-
tiveness. Costs (investment) of intervention will be esti-
mated from the societal perspective which includes costs 
of the intervention programme and costs borne by the 
beneficiaries of the programme.
Effectiveness will be measured in natural units such 
as the number of successfully treated patients, the num-
ber of life years gained, the number of symptom days 
averted, and number of deaths and disabilities averted. 
Incremental cost-effectiveness ratio will be calculated to 
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estimate the cost for an additional outcome by employ-
ing TTd+VC in comparison with TTd alone. Further, 
cost-benefit analysis (CBA) will be conducted to assess 
the economic viability of TTD+VC. In CBA, benefits of 
the intervention programme in terms of total foregone 
cost-of-illness (monetary unit) due to reduced morbidity 
will be calculated and subtracted from the total cost of 
intervention for calculating the net benefits. If we get the 
value of the net benefit more than zero, the intervention 
will be considered as economically viable [35].
Structured questionnaires will be used for collect-
ing data on the costs of intervention alternatives (TTd 
and TTd+VC). Budget and expenditure of the interven-
tion programmes will be reviewed, and key management 
staff will be interviewed for identifying the cost items 
and their validation [36, 37]. For estimating the foregone 
costs of illness, i.e. benefits of the intervention in mon-
etary unit) due to intervention, we shall collect data from 
relevant patients and their healthcare providers using 
structured pretested questionnaires. Direct medical (con-
sultation, medicines, diagnostic tests) and non-medical 
costs (like, food, transport, lodging) as well as indirect 
costs (income loss of the patients and caregivers) will be 
captured in foregone Cost of Illness analysis (COI) [35].
Discussion
Recent surveys indicate persistence of onchocerciasis 
transmission following 12 rounds at coverage ≥ 65% in 
South West Cameroon [7]. These data highlight that a 
transition from control to elimination with the current 
CDTi strategy is complicated by multiple factors. A low 
participation rate to annual IVM MDA has been identi-
fied in SW Cameroon, where self-reported adherence 
is significantly associated with onchocerciasis mf skin 
infection status and intensity of infection [7, 38–40]. 
Multiple societal factors culminate in inadequacy of 
adherence and/or participation ranging from IVM ‘treat-
ment fatigue’, programmatic challenges faced the local 
health system and perceived risks of adverse reactions to 
IVM, including knowledge of L. loa related SAE experi-
ences [8, 9, 41].
Two WHO-endorsed alternative approaches, with the 
potential to circumvent IVM MDA-specific drawbacks, 
are: oral treatment with the macrofilaricide, DOX 
and localised ground-larviciding vector control with 
temephos. Whilst prior implementations of both have 
demonstrated their potential to accelerate onchocer-
ciasis elimination, the parasitological and transmission 
impact of combining the two strategies has not before 
been evaluated [18, 20, 42]. Further, societal accept-
ability of these approaches in an area of low CDTi par-
ticipation has not been detailed. Further, the financial 
feasibility of implementing either of these approaches 
has not been prior interrogated.
Here we have detailed the Department for Interna-
tional Development (DfID) funded COUNTDOWN 
inter-disciplinary research protocol for implementation 
of a test-and-treat with DOX alone or combined with 
temephos ground larviciding.
We hypothesise that through offering alterna-
tive approaches to IVM and engaging communities 
throughout the process there will be lasting positive 
impacts that will contribute to addressing some of the 
challenges and concerns faced by communities. We 
hypothesise that by offering these alternatives to IVM, 
the poor community perception toward onchocerciasis 
elimination can be overcome. Further, we predict that 
a sufficient uptake of DOX treatment, a macrofilaricide 
with a superior range of anti-filarial efficacies which 
does not cause loiasis-associated SAE, potentially in 
combination with vector control, will result in a signifi-
cant (minimum 37%) decline in community prevalence 
of O. volvulus skin infection. The cost of implementa-
tion will be accurately recorded and reported, along 
with patient and health care worker perceptions of the 
interventions, so that future elimination programmes 
can consider the acceptability and feasibility of scaling 
up these approaches.
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